FDA urged to approve soy health claim

FDA has been considering the claim for nearly a year. There is significant scientific evidence to support the claim, and therefore FDA has no right to delay approval, GMA told the agency. The association said it would be reasonable for FDA to require a company to provide substantiation for a soy-protein-coronary heart disease health claim on a label within a "reasonable period of time" following a written request by FDA to the company headquarters.